Urologix, Inc. reported unaudited earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported sales of $2,796,000 compared to $3,356,000 a year ago. Operating loss was $153,000 compared to $1,467,000 a year ago. Loss before income taxes was $349,000 compared to $1,646,000 a year ago. Net loss was $349,000 or $0.02 per basic and diluted share compared to $1,664,000 or $0.08 per basic and diluted share a year ago. The sequential and year-over-year decrease in revenue was driven by a decrease in both Cooled ThermoTherapy™ and Prostiva® unit sales. The year-over-year decline was partially due to changes from restructuring launched in April 2014.

For the nine months period, the company reported sales of $8,896,000 compared to $10,941,000 a year ago. Operating loss was $528,000 compared to $3,522,000 a year ago. Loss before income taxes was $1,134,000 compared to $4,037,000 a year ago. Net loss was $1,143,000 or $0.05 per basic and diluted share compared to $4,083,000 or $0.19 per basic and diluted share a year ago. Net cash used in operating activities was $172,000 compared to $1,439,000 a year ago. Purchase of property and equipment was $8,000 compared to $28,000 a year ago. Purchases of intellectual property were $15,000 compared to $7,000 a year ago.